30/03/2015 12:16:06 Free Membership Login

Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
03/26/20159:01AMTMF3 Things You Need to Know About XOMA Corp.
http://www.fool.com/investing/general/2015/03/26/3-things-you-need-to-know-about-xoma-corp.aspx?source=eptadnlnk0000002 More...>>
03/24/20158:21AMSEEKXOMA Is Still In A Waiting Game
http://seekingalpha.com/article/3023816-xoma-is-still-in-a-waiting-game?source=partner_advfn More...>>
03/11/20159:52PMSEEKXOMA's (XOMA) CEO John Varianon Q4 2014Results - Earnings Call Transcript
http://seekingalpha.com/article/2993826-xomas-xoma-ceo-john-varianon-q4-2014results-earnings-call-transcript?source=partner_advfn More...>>
03/11/20154:01PMGLOBEXOMA Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2014 Financial Results
BERKELEY, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported its operational highlights and financial results for the quarter and year ended December 31, 2014. Recent Highlights: Advanced all gevokizumab clinical... More...>>
03/07/20154:05PMGLOBEXOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
- Results show XOMA 358 reduces insulin receptor signaling and increased glucose production after exogenous insulin injection - XOMA 358 shows potential for treatment of hyperinsulinemic hypoglycemia conditions BERKELEY, Calif., March 7, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery... More...>>
03/05/20154:05PMGLOBEXOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015
BERKELEY, Calif., March 5, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the results from its Phase 1 first-in-human study of XOMA 358, an allosteric modulating monoclonal antibody that binds to insulin receptors and attenuates... More...>>
03/03/20157:00AMGLOBEXOMA Announces Retirement of Fred Kurland and Appointment of Thomas Burns as Chief Financial Officer
BERKELEY, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced Thomas Burns, Vice President, Finance, will succeed Fred Kurland as Chief Financial Officer when Mr. Kurland retires from his role as Vice President, Finance... More...>>
02/26/20153:22PMGLOBEXOMA to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Webcast on March 11
BERKELEY, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, March 11, 2015, at 4:30 p.m. Eastern Standard Time to discuss fourth quarter and full year 2014 financial... More...>>
02/18/201512:36PMGLOBEXOMA to Present at Upcoming Investor Conferences
BERKELEY, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today members of its management team are scheduled to present at three upcoming investor conferences. The details are as follows: RBC Capital Markets Global... More...>>
07/30/20141:15PMGLOBEXOMA to Announce Second Quarter 2014 Financial Results and Host Webcast on August 7
BERKELEY, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, August 7, 2014, at 4:30 p.m. Eastern Daylight Time to discuss second quarter 2014 financial results and provide... More...>>
06/30/20144:01PMGLOBEXOMA Call Today at 4:30pm ET/1:30pm PT to Confirm Communication Plan for EYEGUARD(TM)-B Clinical Program
BERKELEY, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call today, Monday, June 30, 2014, at 4:30 p.m. Eastern time to confirm the communication plan for its EYEGUARD™-B clinical... More...>>
05/28/20143:00PMGLOBEXOMA to Present at the Jefferies Global Healthcare Conference
BERKELEY, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company's Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on June 3, 2014, at 2:00 p.m... More...>>
05/12/20143:30PMGLOBEXOMA to Present at the Bank of America Merrill Lynch Health Care Conference
BERKELEY, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company's Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Bank of America Merrill... More...>>
05/09/20144:00PMZACKSXOMA Posts Wider Q1 Loss - Analyst Blog
XOMA Corporation’s (XOMA) shares declined 18.5% after the company reported wider-than-expected loss per share in the first quarter of 2014 and slower-than-expected patient enrolment in two phase III studies being conducted with gevokizumab. The company posted a loss of 23 cents per share, wider than the Zacks Consensus... More...>>
05/07/20144:01PMGLOBEXOMA Reports First Quarter 2014 Operational Highlights and Financial Results
BERKELEY, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its operational highlights and financial results for the first quarter ended March 31, 2014. First Quarter 2014 Operational Highlights Met with the U.S... More...>>
04/30/20141:25PMGLOBEXOMA to Announce First Quarter 2014 Financial Results and Host Webcast on May 7
BERKELEY, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, May 7, 2014, at 4:30 p.m. Eastern time to discuss first quarter 2014 financial results and provide an update... More...>>
04/28/20149:00AMGLOBEXOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum
BERKELEY, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that based on its meeting with the U.S Food and Drug Administration (FDA), the Company is finalizing its plans for a gevokizumab Phase 3 program in pyoderma... More...>>
03/19/20148:00AMPRNUSHealthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Or...
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, March 19, 2014 NEW YORK, March 19, 2014 /PRNewswire/ -- Today, Analysts... More...>>
03/06/201412:22PMPRNUSTechnical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia
Technical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia PR Newswire NEW YORK, March 6, 2014 NEW YORK, March 6, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The trading session on Wednesday, March 05, 2014 ended on a mixed note as the Dow Jones Industrial... More...>>
03/04/20144:57PMGLOBEXOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
BERKELEY, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced 2013 operational highlights and financial results for the fourth quarter and year ended December 31, 2013. 2013 Operational Highlights Announced the selection... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq xoma150330 12:16